<SEC-DOCUMENT>0001193125-19-014871.txt : 20190123
<SEC-HEADER>0001193125-19-014871.hdr.sgml : 20190123
<ACCEPTANCE-DATETIME>20190123165534
ACCESSION NUMBER:		0001193125-19-014871
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20190123
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20190123
DATE AS OF CHANGE:		20190123

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			CONMED CORP
		CENTRAL INDEX KEY:			0000816956
		STANDARD INDUSTRIAL CLASSIFICATION:	ELECTROMEDICAL & ELECTROTHERAPEUTIC APPARATUS [3845]
		IRS NUMBER:				160977505
		STATE OF INCORPORATION:			NY
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-16093
		FILM NUMBER:		19537899

	BUSINESS ADDRESS:	
		STREET 1:		525 FRENCH ROAD
		CITY:			UTICA
		STATE:			NY
		ZIP:			13502
		BUSINESS PHONE:		315-624-3208

	MAIL ADDRESS:	
		STREET 1:		525 FRENCH ROAD
		CITY:			UTICA
		STATE:			NY
		ZIP:			13502
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>d696818d8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<HTML><HEAD>
<TITLE>Form 8-K</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Washington, D.C. 20549 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>FORM <FONT
STYLE="white-space:nowrap">8-K</FONT> </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>CURRENT
REPORT </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Pursuant to Section&nbsp;13 or 15(d) </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>of the Securities Exchange Act of 1934 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Date of Report (Date of earliest event reported): January&nbsp;23, 2019 </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman" ALIGN="center"><B>CONMED CORPORATION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Exact name of registrant as specified in its charter) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="34%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"><B>New York</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B><FONT STYLE="white-space:nowrap">0-16093</FONT></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B><FONT STYLE="white-space:nowrap">16-0977505</FONT></B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(State or other Jurisdiction</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>of Incorporation)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Commission</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>File Number)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(IRS Employer</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Identification No.)</B></P></TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="50%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"><B>525 French Road</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"><B>Utica, New York</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>13502</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" ALIGN="center"><B>(Address of Principal Executive Offices)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>(Zip Code)</B></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Registrant&#146;s telephone number, including area code: (315)
<FONT STYLE="white-space:nowrap">797-8375</FONT> </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Former name or former address if changed since last report.) </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Check the appropriate box below if the Form <FONT STYLE="white-space:nowrap">8-K</FONT> filing is intended to simultaneously satisfy the filing obligation of
the registrant under any of the following provisions: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Soliciting material pursuant to Rule <FONT STYLE="white-space:nowrap">14a-12</FONT> under the Exchange Act (17
CFR <FONT STYLE="white-space:nowrap">240.14a-12)</FONT> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><FONT STYLE="white-space:nowrap">Pre-commencement</FONT> communications pursuant to Rule <FONT
STYLE="white-space:nowrap">14d-2(b)</FONT> under the Exchange Act (17 CFR <FONT STYLE="white-space:nowrap">240.14d-2(b))</FONT> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><FONT STYLE="white-space:nowrap">Pre-commencement</FONT> communications pursuant to Rule <FONT
STYLE="white-space:nowrap">13e-4(c)</FONT> under the Exchange Act (17 CFR <FONT STYLE="white-space:nowrap">240.13e-4(c))</FONT> </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this
chapter) or Rule <FONT STYLE="white-space:nowrap">12b-2</FONT> of the Securities Exchange Act of 1934 <FONT STYLE="white-space:nowrap">(&#167;240.12b-2</FONT> of this chapter). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Emerging growth company &#9744; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If an emerging growth company,
indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&nbsp;13(a) of the Exchange Act. &#9744; </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Item&nbsp;8.01 Other Events. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On January&nbsp;23, 2019, CONMED Corporation issued a press release to announce that it intends to offer $275&nbsp;million aggregate principal
amount of convertible senior notes due 2024 in a private placement. A copy of this press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Item&nbsp;9.01 Financial Statements and Exhibits. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(d)&nbsp;&nbsp;&nbsp;&nbsp;<U>Exhibits</U></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD WIDTH="92%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Exhibit<BR>No.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; ">Description of Exhibit</P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>99.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="d696818dex991.htm">Press Release, dated January&nbsp;23, 2019, issued by CONMED Corporation. </A></TD></TR>
</TABLE>
</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SIGNATURES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned
hereunto duly authorized. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="12%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">CONMED CORPORATION</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">(Registrant)</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Todd W. Garner</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Todd W. Garner</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Executive Vice President</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">and Chief Financial
Officer</P></TD></TR>
</TABLE></DIV> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Date: January&nbsp;23, 2019 </P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>d696818dex991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.1 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="51%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="47%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">


<IMG SRC="g696818g0123032116341.jpg" ALT="LOGO">
</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>NEWS RELEASE </B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:2.00em; font-size:10pt; font-family:Times New Roman"><B>CONTACT:</B></P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:2.00em; font-size:10pt; font-family:Times New Roman"><B></B><B><I>CONMED Corporation</I></B><B></B></P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:2.00em; font-size:10pt; font-family:Times New Roman"><B>Todd Garner</B></P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:2.00em; font-size:10pt; font-family:Times New Roman"><B>Chief Financial Officer</B></P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:2.00em; font-size:10pt; font-family:Times New Roman"><B><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">315-624-3317</FONT></FONT></B></P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:2.00em; font-size:10pt; font-family:Times New Roman"><B>ToddGarner@conmed.com</B></P></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CONMED Corporation Announces Private Offering of $275 Million of Convertible Senior Notes </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Utica, New York, January</B><B></B><B>&nbsp;23, 2019 &#151; CONMED Corporation (NASDAQ: CNMD)</B> today announced that it intends to offer, subject to
market conditions and other factors, $275&nbsp;million aggregate principal amount of its convertible senior notes due 2024 in a private offering to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended
(the &#147;Securities Act&#148;). In connection with the offering of the notes, CONMED expects to grant the initial purchasers an option to purchase, during a <FONT STYLE="white-space:nowrap">13-day</FONT> period beginning on, and including, the
first day on which the notes are issued, up to an additional $41.25&nbsp;million aggregate principal amount of the notes. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">CONMED intends to use a portion
of the net proceeds from the offering of the notes to pay the cost of certain convertible note hedge transactions, taking into account the proceeds to CONMED of certain warrant transactions, each as described below. CONMED intends to use the
remaining net proceeds from the offering of the notes, together with borrowings under its new credit facilities and its cash on hand, to finance the acquisition (the &#147;Buffalo Filter Acquisition&#148;) of Buffalo Filter LLC and Palmerton
Holdings, Inc. The offering of the notes is not conditioned on the consummation of the Buffalo Filter Acquisition and there can be no assurance that the Buffalo Filter Acquisition will be consummated. If the Buffalo Filter Acquisition is not
consummated, CONMED intends to use the remaining net proceeds from the notes offering for general corporate purposes. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The notes will be CONMED&#146;s
general senior unsecured obligations and will rank equally in right of payment with all of CONMED&#146;s existing and future unsubordinated debt, and senior in right of payment to all of CONMED&#146;s future subordinated debt. The notes will be
effectively subordinated to all of CONMED&#146;s existing and future secured debt, including any borrowings outstanding under its credit facilities, to the extent of the value of the assets securing such indebtedness. The notes will be structurally
subordinated to all of CONMED&#146;s subsidiaries&#146; existing and future liabilities and obligations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The notes will mature on February&nbsp;1, 2024,
unless earlier repurchased or converted. The initial conversion rate, interest rate and certain other terms of the notes will be determined by negotiations between CONMED and the initial purchasers. Prior to November&nbsp;1, 2023, the notes will be
convertible only upon satisfaction of certain conditions and during certain periods, and thereafter, the notes will be convertible at any time until the close of business on the second scheduled trading day immediately preceding the maturity date.
Upon conversion, CONMED will satisfy its conversion obligation by paying or delivering, as applicable, shares of its common stock, cash or a combination of shares of its common stock and cash, at CONMED&#146;s election. </P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If the option granted to the initial purchasers to purchase additional notes is exercised, CONMED may sell
additional warrants and CONMED may use a portion of the proceeds from the sale of such additional notes, together with the proceeds from the sale of the additional warrants, to enter into additional convertible note hedge transactions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In connection with the pricing of the notes, CONMED expects to enter into privately negotiated convertible note hedge transactions with one or more of the
initial purchasers or their respective affiliates (the &#147;option counterparties&#148;). The convertible note hedge transactions will cover, subject to customary anti-dilution adjustments substantially similar to those applicable to the notes, the
same number of shares of CONMED&#146;s common stock that will initially underlie the notes, and are expected generally to reduce the potential dilution to CONMED&#146;s common stock and/or offset any potential cash payments CONMED is required to
make in excess of the principal amount upon conversion of the notes in the event that the market price of CONMED&#146;s common stock is greater than the strike price of the convertible note hedge transactions. CONMED also expects to concurrently
enter into warrant transactions with the option counterparties relating to the same number of shares of CONMED&#146;s common stock, subject to customary anti-dilution adjustments. The warrant transactions could separately have a dilutive effect if
the market price of CONMED&#146;s common stock exceeds the strike price of the warrant transactions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">CONMED has been advised by the option counterparties
that, in connection with establishing their initial hedge position with respect to the convertible note hedge transactions and warrant transactions, the option counterparties and/or their respective affiliates expect to purchase shares of
CONMED&#146;s common stock in secondary market transactions and/or enter into various derivative transactions with respect to CONMED&#146;s common stock concurrently with, or shortly after, the pricing of the notes, including with certain investors
in the notes. This activity could increase (or reduce the size of any decrease in) the market price of CONMED&#146;s common stock or the notes at that time. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">CONMED has also been advised by the option counterparties that the option counterparties or their respective affiliates may modify their hedge positions by
entering into or unwinding various derivative transactions with respect to CONMED&#146;s common stock and/or purchasing or selling CONMED&#146;s common stock or other of CONMED&#146;s securities or instruments, including the notes, in secondary
market transactions following the pricing of the notes and prior to the maturity of the notes. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The option counterparties may choose to engage in, or to
discontinue engaging in, any of these transactions with or without notice at any time, and their decisions will be in their sole discretion. The effect, if any, of such activities of the option counterparties, including direction or magnitude, on
the market price of CONMED&#146;s common stock or the price of the notes will depend on a variety of factors, including market conditions, and cannot be ascertained at this time. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The notes will be offered to qualified institutional buyers pursuant to Rule 144A under the Securities Act. The offer and sale of the notes and the shares of
common stock issuable upon conversion of the notes, if any, have not been registered under the Securities Act or the securities laws of any other jurisdiction, and the notes and any such shares may not be offered or sold absent registration or an
applicable exemption from such registration requirements. </P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This press release shall not constitute an offer to sell or a solicitation of an offer to buy any
securities, including the notes or CONMED common stock, nor shall there be any sale of securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities
laws of any such state or jurisdiction. </P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About CONMED Corporation </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">CONMED is a medical technology company that provides surgical devices and equipment for minimally invasive procedures. The Company&#146;s products are used by
surgeons and physicians in a variety of specialties, including orthopedics, general surgery, gynecology, neurosurgery, thoracic surgery and gastroenterology. CONMED has a direct selling presence in 19 countries, and international sales constitute
approximately 50% of the Company&#146;s total sales. Headquartered in Utica, New York, the Company employs approximately 3,100 people. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Forward-Looking
Statements </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This press release contains forward-looking statements based on certain assumptions and contingencies that involve risks and uncertainties,
which could cause actual results, performance, or trends to differ materially from those expressed in the forward-looking statements herein or in previous disclosures. Forward-looking statements include, but are not limited to, statements regarding
CONMED&#146;s completion of the offering, the anticipated principal amount of securities sold, the final terms of the offering, CONMED&#146;s anticipated use of proceeds and the Buffalo Filter Acquisition. In addition to general industry and
economic conditions, factors that could cause actual results to differ materially from those in the forward-looking statements may include, but are not limited to, CONMED&#146;s ability to meet the closing conditions required for the consummation of
the offering and the risk factors discussed in CONMED&#146;s Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> for the fiscal year ended December&nbsp;31, 2017 and listed under the heading <I>Forward-Looking Statements</I> in
CONMED&#146;s most recently filed Form <FONT STYLE="white-space:nowrap">10-Q.</FONT> Any and all forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and relate to
CONMED&#146;s performance on a going-forward basis. CONMED believes that all forward-looking statements made by it have a reasonable basis, but there can be no assurance that management&#146;s expectations, beliefs or projections as expressed in the
forward-looking statements will actually occur or prove to be correct. </P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g696818g0123032116341.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g696818g0123032116341.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !  .\# 2(  A$! Q$!_\0
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M1 ER=-TLYY,!V[N.<'GOTZT >QT5Y9X/^+WV_6$\/^*].;1M99@D892(Y">
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M?)*W)V9.P#\.?QKT^O,O@AXJMM:\"VNEM*HU#2QY$D1/S% ?E;'ICC\*]-H
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MGXVU/<]_J<SK&[#JF[+,/JW'_ : ,C3H$\(_M-M:)&(;/48=D*KP K1@@?\
M?:8JJWB?2_"?[1WB'4M6E:*V,/E!E7<=Q2+'\C5[XWJVC?$3P?XC4A45U5B#
M@_NY QY^CTNE:?9:I^TUXAM[ZVBN8?LQ8)(NX9V18- '9#XY>!B<?VA,/^V)
MKE_ AS^T=XO(Z&VD(_[[BKU/_A#?#7_0$L?^_(KRSP+Q^T?XP [6\@_\?BH
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M]M)'"Q.!N*D#GMS6E10!P>IW<_B#28-!L-'O;'4(YK=BTEN4CL]CABRN1M;
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H#!K$7C*\&K1^88=/BACO47"7(\QR#C^%L'D>O(X-=?10 4444 ?_V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
